Tech News: ViroCell Biologics

VIROCELL BIOLOGICS: Viral vectors

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

One of the founders of ViroCell is Farzin Farzaneh, Professor of Molecular Medicine at King’s College London, and it expects to employ more than 50 professionals in the UK by the end of 2021.

In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector